Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigator-initiated, Placebo-controlled, Double-blind, Multi-center, Randomized Trial to Assess the Efficacy and Safety of Adrecizumab in Subjects With Cardiogenic Shock

NCT03989531 is registered in ClinicalTrials.gov with Dr. med. Mahir Karakas as lead sponsor.

NCT NCT03989531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03989531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigator-initiated, Placebo-controlled, Double-blind, Multi-center, Randomized Trial to Assess the Efficacy and Safety of Adrecizumab in Subjects With Cardiogenic Shock
Lead sponsor
Dr. med. Mahir Karakas
Phase
Phase 2/3
Overall status
Completed
Start date
April 4, 2019
Completion date
April 26, 2021
Enrollment
150 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cardiogenic shock, endothelial dysfunction